Search research articles
Contact Us
Filters
Showing results (1-10 of 77) with videos related to
Page
of 8
Sort By:
Expert Opinion on Therapeutic Patents
|
September 9, 2017
Deuterated drugs; updates and obviousness analysis
Graham S Timmins
Expert Opinion on Drug Discovery
|
October 1, 2019
What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?
Graham S Timmins
Trends in Microbiology
|
March 25, 2015
Detecting virulence and drug-resistance mycobacterial phenotypes in vivo
Graham S Timmins
Expert Opinion on Therapeutic Patents
|
July 29, 2016
Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literature
Graham S Timmins
Expert Opinion on Therapeutic Patents
|
July 30, 2014
Deuterated drugs: where are we now?
Graham S Timmins
Molecular Microbiology
|
November 1, 2006
Mechanisms of action of isoniazid
Graham S Timmins, Vojo Deretic
Expert Opinion on Drug Metabolism & Toxicology
|
February 6, 2019
Enhancement of lung levels of antibiotics by ambroxol and bromhexine
Vojo Deretic, Graham S Timmins
Journal of Photochemistry and Photobiology. B, Biology
|
December 1, 1993
An EPR spin trapping study of albumin protein radicals formed by the photodynamic action of haematoporphyrin
G S Timmins, M J Davies
FEMS Microbiology Letters
|
April 3, 1999
Shift-down in growth rate rather than high cell density induces toxic shock syndrome toxin-1 gene expression in Staphylococcus aureus
B S Timmins, K T Holland
Journal of Breath Research
|
May 17, 2019
Potential for breath test diagnosis of urease positive pathogens in lung infections
William R Bishai, Graham S Timmins
Page
of 8
Search research articles
Search
Showing results (1-10 of 77) with videos related to
Sort By:
Page
of 8
Expert Opinion on Therapeutic Patents
|
September 9, 2017
Deuterated drugs; updates and obviousness analysis
Graham S Timmins
Expert Opinion on Drug Discovery
|
October 1, 2019
What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?
Graham S Timmins
Trends in Microbiology
|
March 25, 2015
Detecting virulence and drug-resistance mycobacterial phenotypes in vivo
Graham S Timmins
Expert Opinion on Therapeutic Patents
|
July 29, 2016
Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literature
Graham S Timmins
Expert Opinion on Therapeutic Patents
|
July 30, 2014
Deuterated drugs: where are we now?
Graham S Timmins
Molecular Microbiology
|
November 1, 2006
Mechanisms of action of isoniazid
Graham S Timmins, Vojo Deretic
Expert Opinion on Drug Metabolism & Toxicology
|
February 6, 2019
Enhancement of lung levels of antibiotics by ambroxol and bromhexine
Vojo Deretic, Graham S Timmins
Journal of Photochemistry and Photobiology. B, Biology
|
December 1, 1993
An EPR spin trapping study of albumin protein radicals formed by the photodynamic action of haematoporphyrin
G S Timmins, M J Davies
FEMS Microbiology Letters
|
April 3, 1999
Shift-down in growth rate rather than high cell density induces toxic shock syndrome toxin-1 gene expression in Staphylococcus aureus
B S Timmins, K T Holland
Journal of Breath Research
|
May 17, 2019
Potential for breath test diagnosis of urease positive pathogens in lung infections
William R Bishai, Graham S Timmins
Page
of 8